Pacira Pharmaceuticals buy Royal Bank of Canada
Start price
01.03.24
/
50%
€26.20
Target price
01.03.25
€41.56
Performance (%)
-46.56%
Price
03.10.24
€14.10
Summary
This prediction is currently active. Massive losses of -46.56% have been the result for the BUY prediction by Royal_Bank_of_Canada. This prediction currently runs until 01.03.25. The prediction end date can be changed by Royal_Bank_of_Canada at any time. Royal_Bank_of_Canada has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Pacira Pharmaceuticals | 9.302% | 9.302% |
iShares Core DAX® | -1.114% | 3.430% |
iShares Nasdaq 100 | 1.816% | 6.911% |
iShares Nikkei 225® | 2.113% | 5.501% |
iShares S&P 500 | 2.038% | 5.327% |
Comments by Royal_Bank_of_Canada for this prediction
In the thread Pacira Pharmaceuticals diskutieren
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target lowered by analysts at Royal Bank of Canada from $53.00 to $45.00. They now have an "outperform" rating on the stock.
Ratings data for PCRX provided by MarketBeat
Stopped prediction by Royal_Bank_of_Canada for Pacira Pharmaceuticals
Pacira Pharmaceuticals
Start price
Target price
Perf. (%)
€19.10
31.07.24
31.07.24
€34.16
31.07.25
31.07.25
-20.94%
03.10.24
03.10.24
Pacira Pharmaceuticals
Start price
Target price
Perf. (%)
€28.40
03.11.23
03.11.23
€54.04
03.11.24
03.11.24
-46.83%
03.10.24
03.10.24
Pacira Pharmaceuticals
Start price
Target price
Perf. (%)
€27.40
03.10.23
03.10.23
€65.04
03.10.24
03.10.24
-45.99%
04.10.24
04.10.24
Pacira Pharmaceuticals
Start price
Target price
Perf. (%)
€34.80
03.08.23
03.08.23
€62.07
03.08.24
03.08.24
-47.13%
04.08.24
04.08.24
Pacira Pharmaceuticals
Start price
Target price
Perf. (%)
€40.00
01.03.23
01.03.23
€71.20
01.03.24
01.03.24
-34.50%
02.03.24
02.03.24